explore -WSS

explore

author：leisure time 2025-09-29 23:27:13 Page View：6

SAN DIEGO — After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting annual growth of 1% compared to the previous year.

The market’s response was swift. Minutes after the company issued its press release, shares in Illumina dipped from $184.49 to below $172 during after-hours trading.

In its release, Illumina noted that it expects revenue from the company’s core business to be essentially the same this year compared to last, and that it expects revenue from Grail, the cancer diagnostics company that Illumina acquired for $8 billion in the fall of 2021, to remain in the range of $90 and $100 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Russian and Belarusian players banned from a women's tennis tournament in Prague
Next article： Jerome Adams on the need for new antivirals for Covid

explore

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Judge orders hearing on Trump's motion to disqualify Fulton County DA

5:51RepublicanpresidentialcandidateformerpresidentDonaldTrumpspeaksattheRepublicanPartyofIowa's2023L

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Snowpack in the West is melting rapidly. Where will all that extra water go?

6:52Asthesnowpackmelts,waterflowsswiftlyinAlderCreek,onApril26,2023,inYosemiteNationalPark,Calif.Fra